Sept. 3, 2025
| Today’s news and insights for biopharma leaders
Updated findings from Wave’s pioneering trial continued to show its RNA editing therapy is working as intended, but wasn’t as effective in testing as investors had hoped.
|
The letter cites turmoil at the CDC, which is reeling from the firing of Director Susan Monarez and the departure of at least four high-level leaders last week.
|
The alliance, which could be worth more than $5 billion, is one of a handful of deals Novartis has struck with China-based biotechs in recent years.
|
Making tomorrow’s breakthroughs a reality for the patients who need therapies today.
|
The biotech started by Loxo founder Josh Bilenker and former Novartis executive Jeff Engelman has advanced three cancer drugs to Phase 1 trials.
|
UPDATED
Biopharmaceutical firms in the U.S. and Europe are turning to China’s biotech sector for new medicines, with licensing hitting a record pace in 2025. Follow this year’s dealmaking with this database.
|
|
Clinical trial enrollment delays affect 80% of studies, costing sponsors time and money. Learn how centralized recruitment can accelerate enrollment while preserving site autonomy in this playbook.
|
|
From Our Library
Trendline
Supported by Bio-Rad
|
Trendline
Supported by Catalent
|
Playbook
Custom content for PharmaForceIQ
|
Trendline
Supported by EVERSANA
|
| 
